دورية أكاديمية
أعرض في EDS

Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development.

التفاصيل البيبلوغرافية
العنوان: Features of functional and dysfunctional CD8+ T cells to guide HIV vaccine development.
المؤلفون: Bhattacharyya S; Ragon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts 02139., Crain CR; Ragon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts 02139., Goldberg B; Ragon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts 02139., Gaiha GD; Ragon Institute of Mass General, MIT and Harvard, Cambridge, Massachusetts 02139.; Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts 02115.
المصدر: Current opinion in HIV and AIDS [Curr Opin HIV AIDS] 2023 Sep 01; Vol. 18 (5), pp. 257-263. Date of Electronic Publication: 2023 Jul 18.
نوع المنشور: Review; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101264945 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1746-6318 (Electronic) Linking ISSN: 1746630X NLM ISO Abbreviation: Curr Opin HIV AIDS Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Hagerstown, MD : Lippincott Williams & Wilkins, c2006-
مواضيع طبية MeSH: HIV Infections* , AIDS Vaccines*, Humans ; CD8-Positive T-Lymphocytes ; Vaccination ; Vaccine Development
مستخلص: Purpose of Review: CD8+ T cell responses are a key component of the host immune response to human immunodeficiency virus (HIV) but vary significantly across individuals with distinct clinical outcomes. These differences help inform the qualitative features of HIV-specific CD8+ T cells that we should aim to induce by vaccination.
Recent Findings: We review previous and more recent findings on the features of dysfunctional and functional CD8+ T cell responses that develop in individuals with uncontrolled and controlled HIV infection, with particular emphasis on proliferation, cytotoxic effector function, epitope specificity, and responses in lymph nodes. We also discuss the implications of these findings for both prophylactic and therapeutic T cell vaccine development within the context of T cell vaccine trials.
Summary: The induction of HIV specific CD8+ T cell responses is an important goal of ongoing vaccine efforts. Emerging data on the key features of CD8+ T cell responses that distinguish individuals who spontaneously control from those with progressive disease continues to provide key guidance.
(Copyright © 2023 Wolters Kluwer Health, Inc. All rights reserved.)
References: Immunity. 2008 Dec 19;29(6):1009-21. (PMID: 19062316)
Nat Med. 2020 Jun;26(6):932-940. (PMID: 32393800)
J Virol. 2016 Nov 28;90(24):11168-11180. (PMID: 27707919)
J Transl Med. 2015 Feb 15;13:60. (PMID: 25879820)
Front Immunol. 2021 Jun 04;12:647688. (PMID: 34149690)
J Acquir Immune Defic Syndr. 2019 Oct 1;82(2):211-219. (PMID: 31513075)
Nat Med. 2022 Aug;28(8):1619-1629. (PMID: 35970920)
Science. 2016 Dec 2;354(6316):1160-1165. (PMID: 27789795)
Nat Genet. 2021 Oct;53(10):1504-1516. (PMID: 34611364)
Immunity. 2014 Dec 18;41(6):1001-12. (PMID: 25526311)
Blood. 2012 May 17;119(20):4645-55. (PMID: 22490332)
AIDS Res Hum Retroviruses. 1996 Dec 10;12(18):1691-8. (PMID: 8959245)
Immunol Rev. 2019 Nov;292(1):149-163. (PMID: 31883174)
Cell Rep. 2017 Dec 19;21(12):3458-3470. (PMID: 29262326)
Sci Rep. 2016 Oct 05;6:33987. (PMID: 27703185)
PLoS One. 2008;3(12):e3907. (PMID: 19107206)
J Immunol. 2013 Jul 15;191(2):540-4. (PMID: 23772031)
Sci Immunol. 2023 May 19;8(83):eade5872. (PMID: 37205767)
EClinicalMedicine. 2019 Jun 05;11:65-80. (PMID: 31312806)
Nat Immunol. 2021 Aug;22(8):1020-1029. (PMID: 34312547)
Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1976-1981. (PMID: 28159893)
Blood. 2013 Jan 31;121(5):801-11. (PMID: 23233659)
Front Immunol. 2022 Jul 05;13:908697. (PMID: 35865519)
EBioMedicine. 2021 Jan;63:103175. (PMID: 33450518)
Cell Rep. 2021 Jul 13;36(2):109378. (PMID: 34260940)
PLoS Pathog. 2014 Apr 10;10(4):e1004071. (PMID: 24722454)
Hum Vaccin Immunother. 2020 Mar 3;16(3):713-722. (PMID: 31584318)
Nat Metab. 2019 Jul;1(7):704-716. (PMID: 32694646)
Nat Immunol. 2001 Aug;2(8):698-704. (PMID: 11477405)
Nature. 2017 Jul 13;547(7662):222-226. (PMID: 28678784)
Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14. (PMID: 10694578)
Nat Med. 2010 Oct;16(10):1147-51. (PMID: 20890291)
PLoS Pathog. 2015 Sep 17;11(9):e1005142. (PMID: 26379282)
Science. 2019 May 3;364(6439):480-484. (PMID: 31048489)
Immunity. 2021 Oct 12;54(10):2372-2384.e7. (PMID: 34496223)
Nat Immunol. 2021 Aug;22(8):1008-1019. (PMID: 34312545)
PLoS One. 2012;7(7):e40385. (PMID: 22808149)
JCI Insight. 2021 Feb 8;6(3):. (PMID: 33351785)
Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14658-63. (PMID: 26553974)
Science. 2010 Dec 10;330(6010):1551-7. (PMID: 21051598)
Front Immunol. 2018 Jan 25;9:20. (PMID: 29422894)
PLoS One. 2007 Oct 03;2(10):e984. (PMID: 17912361)
Nat Immunol. 2016 Oct;17(10):1187-96. (PMID: 27487330)
Nature. 2006 Sep 21;443(7109):350-4. (PMID: 16921384)
Sci Transl Med. 2019 Dec 18;11(523):. (PMID: 31852798)
Sci Transl Med. 2021 Dec 15;13(624):eabl4097. (PMID: 34910552)
J Exp Med. 2013 Jan 14;210(1):143-56. (PMID: 23254284)
Science. 2022 Dec 2;378(6623):eadd6502. (PMID: 36454825)
J Virol. 2013 May;87(10):5461-7. (PMID: 23468488)
Nat Med. 2006 Oct;12(10):1198-202. (PMID: 16917489)
Nat Med. 2022 Dec;28(12):2611-2621. (PMID: 36302893)
Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14733-8. (PMID: 20679213)
AIDS. 2017 May 15;31(8):1091-1098. (PMID: 28301422)
Nat Rev Immunol. 2023 Mar 31;:. (PMID: 37002288)
Nature. 2016 Aug 2;537(7620):412-428. (PMID: 27501245)
Sci Immunol. 2018 Jun 1;3(24):. (PMID: 29858286)
Science. 2007 Aug 17;317(5840):944-7. (PMID: 17641165)
Nat Immunol. 2002 Nov;3(11):1061-8. (PMID: 12368910)
Nat Med. 1996 Apr;2(4):405-11. (PMID: 8597949)
Blood. 2012 Oct 25;120(17):3466-77. (PMID: 22955926)
Lancet. 2008 Nov 29;372(9653):1881-1893. (PMID: 19012954)
Nat Med. 2007 Jan;13(1):100-6. (PMID: 17187074)
Cell Rep. 2016 Apr 19;15(3):588-598. (PMID: 27068472)
EBioMedicine. 2014 Dec 22;2(1):46-58. (PMID: 26137533)
PLoS Pathog. 2010 May 27;6(5):e1000917. (PMID: 20523897)
Nat Commun. 2023 May 22;14(1):2929. (PMID: 37217466)
Biomed Res Int. 2015;2015:916936. (PMID: 25685816)
N Engl J Med. 1995 Jan 26;332(4):209-16. (PMID: 7808486)
J Virol. 2015 Nov;89(21):10735-47. (PMID: 26269189)
Lancet Infect Dis. 2011 Jul;11(7):507-15. (PMID: 21570355)
Mol Ther. 2016 Apr;24(4):832-42. (PMID: 26743582)
PLoS Pathog. 2007 Nov;3(11):e157. (PMID: 18052528)
PLoS Pathog. 2016 Jan 07;12(1):e1005349. (PMID: 26741490)
N Engl J Med. 2021 Mar 18;384(11):1003-1014. (PMID: 33730454)
Blood. 2006 Jun 15;107(12):4781-9. (PMID: 16467198)
J Infect Dis. 2021 Feb 15;223(12 Suppl 2):32-37. (PMID: 33586771)
Science. 2016 Dec 2;354(6316):1165-1169. (PMID: 27789799)
Nature. 2020 Sep;585(7824):261-267. (PMID: 32848246)
EBioMedicine. 2022 Jul;81:104090. (PMID: 35665682)
Nat Med. 2011 Mar;17(3):366-71. (PMID: 21358627)
Front Immunol. 2020 May 06;11:823. (PMID: 32435247)
Cancer Cell. 2014 Dec 8;26(6):923-937. (PMID: 25465800)
Cell. 2016 Aug 11;166(4):1004-1015. (PMID: 27453467)
Nature. 2023 Jun;618(7963):144-150. (PMID: 37165196)
J Virol. 2012 Jun;86(12):6959-69. (PMID: 22514340)
Life Sci Alliance. 2021 Sep 21;4(11):. (PMID: 34548381)
PLoS One. 2013 Jun 13;8(6):e66065. (PMID: 23785468)
J Virol. 2001 May;75(10):4941-6. (PMID: 11312369)
J Infect Dis. 2009 Feb 1;199(3):419-26. (PMID: 19115949)
Ann Intern Med. 2022 Jan;175(1):95-100. (PMID: 34781719)
معلومات مُعتمدة: DP1 DA058476 United States DA NIDA NIH HHS; DP2 AI154421 United States AI NIAID NIH HHS; R01 AI176533 United States AI NIAID NIH HHS; UM1 AI144462 United States AI NIAID NIH HHS
المشرفين على المادة: 0 (AIDS Vaccines)
تواريخ الأحداث: Date Created: 20230803 Date Completed: 20230804 Latest Revision: 20230917
رمز التحديث: 20230917
مُعرف محوري في PubMed: PMC10503300
DOI: 10.1097/COH.0000000000000812
PMID: 37535040
قاعدة البيانات: MEDLINE
الوصف
تدمد:1746-6318
DOI:10.1097/COH.0000000000000812